GALWAY, Ireland, 15 April 2026 - Boston Scientific Corporation (NYSE: BSX) – a global leader in medical device technology – today announced a €75 million investment in its Galway site,...
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial...
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs....
Pulsed field ablation is emerging as a promising innovation in the treatment of cardiac arrhythmias. By offering a more targeted approach with the potential for improved safety and efficiency, the technology represents a significant step forward in the evolution of electrophysiology care.
Advances in technology and treatment approaches are ushering in a new era for kidney cancer care. From earlier detection to more targeted therapies, innovation is reshaping how the disease is managed and offering new hope for improved patient outcomes.
Sacral neuromodulation is expanding treatment options for patients with bladder and bowel dysfunction, reinforcing Boston Scientific’s growing urology portfolio in Europe. The therapy highlights the company’s focus on innovative solutions that address unmet clinical needs and improve quality of life.
Ureteroscopy is becoming an increasingly important minimally invasive approach for the treatment of kidney stones. By allowing precise visualisation and targeted intervention, it offers an effective alternative to more invasive procedures, helping improve patient outcomes and recovery times.